Lineage Cell Therapeutics (LCTX) Interest Coverage Ratio Growth (3y) (2014 - 2026)
Lineage Cell Therapeutics (LCTX) Interest Coverage Ratio Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -42.41% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 28.11% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -6.89% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 79.27% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 29.47% |
| 10 | Lineage Cell Therapeutics | 267.08 Mn | 203.18 Mn | 1.73 Mn | 63.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 63.29% |
| Dec 31, 2025 | -10.58% |
| Sep 30, 2025 | 70.95% |
| Jun 30, 2025 | 56.07% |
| Mar 31, 2025 | 5.26% |
| Dec 31, 2024 | 27.30% |
| Sep 30, 2024 | 29.29% |
| Jun 30, 2024 | 19.25% |
| Mar 31, 2024 | 57.13% |
| Dec 31, 2023 | 32.76% |
| Sep 30, 2023 | -154.90% |
| Jun 30, 2023 | -110.12% |
| Mar 31, 2023 | -38.70% |
| Dec 31, 2022 | 37.85% |
| Sep 30, 2022 | -23.00% |
| Jun 30, 2022 | -110.98% |
| Mar 31, 2022 | -105.26% |
| Dec 31, 2021 | -657.07% |
| Dec 31, 2020 | -183.86% |
| Dec 31, 2019 | -27.83% |